Intracranial hemorrhage in cancer patients treated with anticoagulation

Thromb Res. 2016 Apr:140 Suppl 1:S60-5. doi: 10.1016/S0049-3848(16)30100-1.

Abstract

Both venous thromboembolism and intracranial metastases are common complications in the setting of primary brain tumors and metastatic malignancies. Anticoagulation is indicated in the presence of cancer-associated thrombosis in order to limit the risk of pulmonary embolism; however, there is reluctance to initiate anticoagulation in the setting of intracranial metastatic disease due to potential for intracranial hemorrhage. Recent evidence suggests that therapeutic anticoagulation can be safely administered in the setting of metastatic brain tumors. This review examines the current understanding of the pathophysiology of intracranial hemorrhage in malignancy, describes the incidence of intracranial hemorrhage in the setting of brain tumors with therapeutic anticoagulation, and outlines management strategies relevant to the treatment of intracranial hemorrhage in the setting of anticoagulation.

Keywords: Anticoagulation; Brain metastases; Intracranial hemorrhage.

Publication types

  • Review

MeSH terms

  • Anticoagulants / adverse effects*
  • Anticoagulants / therapeutic use
  • Blood Coagulation / drug effects
  • Brain / blood supply
  • Brain / drug effects
  • Brain / physiopathology
  • Brain Neoplasms / blood
  • Brain Neoplasms / complications*
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / physiopathology
  • Humans
  • Intracranial Hemorrhages / chemically induced*
  • Intracranial Hemorrhages / complications*
  • Intracranial Hemorrhages / physiopathology
  • Intracranial Hemorrhages / therapy
  • Venous Thromboembolism / blood
  • Venous Thromboembolism / complications*
  • Venous Thromboembolism / drug therapy*
  • Venous Thromboembolism / physiopathology

Substances

  • Anticoagulants